ClinicalTrials.gov
public full text
Public Domain
To Assess the Bioequivalence of Two Pacritinib Drug Product Formulations and FMI Formulation Following Oral Administration in Healthy Subjects
A Phase 1, Open-Label, Single-Dose, Randomized, 2-Period Crossover Study to Assess the Bioequivalence of Two Pacritinib Drug Product Formulations (Phase 3 Clinical Trial \[P3CT\] Formulation \[Reference\] and Final Market Image \[FMI\] Formulation \[Test\]) Following Oral Administration in Healthy Subjects
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Oral Bioequivalence Study of PL 3100 and Naproxen in Healthy Adults#1211396
- Bioequivalence of Extended Release Nifedipine Tablets in Healthy Chinese Subjects#1231684
- Bioavailability of 3 Different Formulations of BI 207127 in Healthy Male Volunteers#1411005
- A Pilot Bioequivalence Study of Pomalidomide#864295
- Pharmacokinetics of Salmeterol (Serevent®) After Inhalation With Metered Dose Inhaler (MDI) and Diskus® in Healthy Male Volunteers#1127593
Record · ID 1432941
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive